Adalimumab significantly reduces inflammation and serum <scp>DKK</scp>‐1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis
Adalimumab significantly reduces inflammation and serum <scp>DKK</scp>‐1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Adalimumab significantly reduces inflammation and serum <scp>DKK</scp>‐1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis have?
Adalimumab significantly reduces inflammation and serum <scp>DKK</scp>‐1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis has 52 citations in the OpenAlex counts ScholarIQ stores.
When was Adalimumab significantly reduces inflammation and serum <scp>DKK</scp>‐1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis published?
Adalimumab significantly reduces inflammation and serum <scp>DKK</scp>‐1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis has 2012 year in the ScholarIQ index.
What is the open-access status of Adalimumab significantly reduces inflammation and serum <scp>DKK</scp>‐1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis?
Adalimumab significantly reduces inflammation and serum <scp>DKK</scp>‐1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis has closed oa status in the ScholarIQ index.
What is the DOI of Adalimumab significantly reduces inflammation and serum <scp>DKK</scp>‐1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis?
The DOI for Adalimumab significantly reduces inflammation and serum <scp>DKK</scp>‐1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis is on the source record.
What is the PMID of Adalimumab significantly reduces inflammation and serum <scp>DKK</scp>‐1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis?
The PMID for Adalimumab significantly reduces inflammation and serum <scp>DKK</scp>‐1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis is on the source record.
What is the OpenAlex record for Adalimumab significantly reduces inflammation and serum <scp>DKK</scp>‐1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis?
The OpenAlex for Adalimumab significantly reduces inflammation and serum <scp>DKK</scp>‐1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis is on the source record.